These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 33850270)

  • 1. A cross-sectional study on gut microbiota in prostate cancer patients with prostatectomy or androgen deprivation therapy.
    Li JKM; Wang LL; Wong CYP; Chiu PKF; Teoh JYC; Kwok HSW; Leung SCH; Wong SH; Tsui SKW; Ng CF
    Prostate Cancer Prostatic Dis; 2021 Dec; 24(4):1063-1072. PubMed ID: 33850270
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term effects of androgen deprivation therapy in prostate cancer patients.
    Basaria S; Lieb J; Tang AM; DeWeese T; Carducci M; Eisenberger M; Dobs AS
    Clin Endocrinol (Oxf); 2002 Jun; 56(6):779-86. PubMed ID: 12072048
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimal PSA Threshold for Androgen-Deprivation Therapy in Patients with Prostate Cancer following Radical Prostatectomy and Adjuvant Radiation Therapy.
    Ahn HK; Lee KS; Kim D; Rha KH; Hong SJ; Chung BH; Koo KC
    Yonsei Med J; 2020 Aug; 61(8):652-659. PubMed ID: 32734728
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Changes in Beck Depression Inventory scores in prostate cancer patients undergoing androgen deprivation therapy or prostatectomy.
    Shin D; Shim SR; Kim CH
    PLoS One; 2020; 15(6):e0234264. PubMed ID: 32542009
    [TBL] [Abstract][Full Text] [Related]  

  • 5. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.
    Heidenreich A; Bastian PJ; Bellmunt J; Bolla M; Joniau S; van der Kwast T; Mason M; Matveev V; Wiegel T; Zattoni F; Mottet N;
    Eur Urol; 2014 Feb; 65(2):467-79. PubMed ID: 24321502
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Response of the insulin-like growth factor (IGF) system to IGF-IR inhibition and androgen deprivation in a neoadjuvant prostate cancer trial: effects of obesity and androgen deprivation.
    Dean JP; Sprenger CC; Wan J; Haugk K; Ellis WJ; Lin DW; Corman JM; Dalkin BL; Mostaghel E; Nelson PS; Cohen P; Montgomery B; Plymate SR
    J Clin Endocrinol Metab; 2013 May; 98(5):E820-8. PubMed ID: 23533230
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adherence to guidelines for androgen deprivation therapy after radical prostatectomy: Swedish population-based study.
    Lycken M; Drevin L; Garmo H; Larsson A; Andrén O; Holmberg L; Bill-Axelson A
    Scand J Urol; 2020 Jun; 54(3):208-214. PubMed ID: 32338176
    [No Abstract]   [Full Text] [Related]  

  • 8. Obesity is associated with castration-resistant disease and metastasis in men treated with androgen deprivation therapy after radical prostatectomy: results from the SEARCH database.
    Keto CJ; Aronson WJ; Terris MK; Presti JC; Kane CJ; Amling CL; Freedland SJ
    BJU Int; 2012 Aug; 110(4):492-8. PubMed ID: 22094083
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy.
    Messing EM; Manola J; Yao J; Kiernan M; Crawford D; Wilding G; di'SantAgnese PA; Trump D;
    Lancet Oncol; 2006 Jun; 7(6):472-9. PubMed ID: 16750497
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Androgen deprivation therapy in prostate cancer: are rising concerns leading to falling use?
    Krahn M; Bremner KE; Tomlinson G; Luo J; Ritvo P; Naglie G; Alibhai SM
    BJU Int; 2011 Nov; 108(10):1588-96. PubMed ID: 21453344
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Androgen deprivation therapy use with post-prostatectomy radiotherapy in the Prostate Cancer Outcomes Registry Victoria.
    Ong WL; Foroudi F; Evans S; Millar J
    J Med Imaging Radiat Oncol; 2019 Feb; 63(1):124-130. PubMed ID: 30295411
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gut environment changes due to androgen deprivation therapy in patients with prostate cancer.
    Kure A; Tsukimi T; Ishii C; Aw W; Obana N; Nakato G; Hirayama A; Kawano H; China T; Shimizu F; Nagata M; Isotani S; Muto S; Horie S; Fukuda S
    Prostate Cancer Prostatic Dis; 2023 Jun; 26(2):323-330. PubMed ID: 35418210
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality.
    Tsai HK; D'Amico AV; Sadetsky N; Chen MH; Carroll PR
    J Natl Cancer Inst; 2007 Oct; 99(20):1516-24. PubMed ID: 17925537
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Changes in physical functioning and muscle strength in men receiving androgen deprivation therapy for prostate cancer: a controlled comparison.
    Gonzalez BD; Jim HSL; Small BJ; Sutton SK; Fishman MN; Zachariah B; Heysek RV; Jacobsen PB
    Support Care Cancer; 2016 May; 24(5):2201-2207. PubMed ID: 26563183
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Androgen deprivation modulates gene expression profile along prostate cancer progression.
    Volante M; Tota D; Giorcelli J; Bollito E; Napoli F; Vatrano S; Buttigliero C; Molinaro L; Gontero P; Porpiglia F; Tucci M; Papotti M; Berruti A; Rapa I
    Hum Pathol; 2016 Oct; 56():81-8. PubMed ID: 27342909
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Depressive symptoms are found to be potential adverse effects of androgen deprivation therapy in older prostate cancer patients: A 15-month prospective, observational study.
    Zhang Z; Yang L; Xie D; Shi H; Li G; Yu D
    Psychooncology; 2017 Dec; 26(12):2238-2244. PubMed ID: 28474429
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Androgen deprivation therapy through bilateral orchiectomy: increased metabolic risks.
    Bo JJ; Zhang C; Zhang LH; Liu P; Sha JJ; Lv JW; Liu DM; Huang YR; Li Z
    Asian J Androl; 2011 Nov; 13(6):833-7. PubMed ID: 21785444
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Androgen deprivation therapy during and after post-prostatectomy radiotherapy in patients with prostate cancer: a case control study.
    Kim M; Song C; Jeong IG; Choi SK; Park M; Shim M; Kim YS; You D; Hong JH; Kim CS; Ahn H
    BMC Cancer; 2018 Mar; 18(1):271. PubMed ID: 29523103
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Complete androgen blockade vs. medical castration alone as adjuvant androgen deprivation therapy for prostate cancer patients following radical prostatectomy: a retrospective cohort study.
    Jin D; Jin K; Chen B; Zhou X; Yuan Q; Zhang Z; Wei Q; Qiu S
    Chin Med J (Engl); 2022 Apr; 135(7):820-827. PubMed ID: 35234695
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quality of Life after Radical Prostatectomy or Watchful Waiting With or Without Androgen Deprivation Therapy: The SPCG-4 Randomized Trial.
    Johansson E; Steineck G; Holmberg L; Johansson JE; Nyberg T; Bill-Axelson A;
    Eur Urol Oncol; 2018 Jun; 1(2):134-142. PubMed ID: 31100237
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.